WO2017129558A1 - Méthodes permettant de prévoir ou de traiter la septicémie et les maladies cardiométaboliques induites par la myélopoïèse - Google Patents
Méthodes permettant de prévoir ou de traiter la septicémie et les maladies cardiométaboliques induites par la myélopoïèse Download PDFInfo
- Publication number
- WO2017129558A1 WO2017129558A1 PCT/EP2017/051418 EP2017051418W WO2017129558A1 WO 2017129558 A1 WO2017129558 A1 WO 2017129558A1 EP 2017051418 W EP2017051418 W EP 2017051418W WO 2017129558 A1 WO2017129558 A1 WO 2017129558A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- apoe
- glutl
- mice
- hspcs
- cells
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 33
- 206010040047 Sepsis Diseases 0.000 title claims abstract description 13
- 208000001145 Metabolic Syndrome Diseases 0.000 title claims abstract description 12
- 239000003112 inhibitor Substances 0.000 claims abstract description 38
- 108091006296 SLC2A1 Proteins 0.000 claims abstract description 27
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 6
- 102000058063 Glucose Transporter Type 1 Human genes 0.000 claims abstract 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 22
- NQRKYASMKDDGHT-UHFFFAOYSA-N (aminooxy)acetic acid Chemical compound NOCC(O)=O NQRKYASMKDDGHT-UHFFFAOYSA-N 0.000 claims description 6
- SOWBFZRMHSNYGE-UHFFFAOYSA-N Monoamide-Oxalic acid Natural products NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 claims description 6
- GNYIJZMBLZXJEJ-UHFFFAOYSA-N n-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide Chemical compound CC(=O)CC(=O)NC1=CC=C(Cl)C(C(F)(F)F)=C1 GNYIJZMBLZXJEJ-UHFFFAOYSA-N 0.000 claims description 3
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 description 108
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 description 108
- 210000001185 bone marrow Anatomy 0.000 description 96
- 241000699670 Mus sp. Species 0.000 description 84
- 210000004027 cell Anatomy 0.000 description 57
- 102000013918 Apolipoproteins E Human genes 0.000 description 44
- 108010025628 Apolipoproteins E Proteins 0.000 description 44
- 230000014509 gene expression Effects 0.000 description 39
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 34
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 34
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 28
- 102100023536 Solute carrier family 2, facilitated glucose transporter member 1 Human genes 0.000 description 22
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 20
- 230000007812 deficiency Effects 0.000 description 20
- 230000001419 dependent effect Effects 0.000 description 20
- 230000000153 supplemental effect Effects 0.000 description 19
- 238000011282 treatment Methods 0.000 description 19
- 239000000203 mixture Substances 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 238000000684 flow cytometry Methods 0.000 description 16
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 102000000646 Interleukin-3 Human genes 0.000 description 15
- 108010002386 Interleukin-3 Proteins 0.000 description 15
- 230000002503 metabolic effect Effects 0.000 description 15
- 230000035755 proliferation Effects 0.000 description 15
- 235000012000 cholesterol Nutrition 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 239000008103 glucose Substances 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 13
- 238000011002 quantification Methods 0.000 description 13
- 230000033228 biological regulation Effects 0.000 description 12
- 230000002414 glycolytic effect Effects 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 238000012423 maintenance Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 11
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 11
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 11
- 230000004190 glucose uptake Effects 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 11
- 210000001616 monocyte Anatomy 0.000 description 11
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 11
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 10
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 description 10
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 10
- 230000007423 decrease Effects 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 235000009200 high fat diet Nutrition 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 230000002438 mitochondrial effect Effects 0.000 description 9
- 210000000066 myeloid cell Anatomy 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 206010021143 Hypoxia Diseases 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 210000002360 granulocyte-macrophage progenitor cell Anatomy 0.000 description 8
- 230000003394 haemopoietic effect Effects 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 210000000440 neutrophil Anatomy 0.000 description 8
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 7
- 108090000994 Catalytic RNA Proteins 0.000 description 7
- 102000053642 Catalytic RNA Human genes 0.000 description 7
- 208000035150 Hypercholesterolemia Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 210000002376 aorta thoracic Anatomy 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 7
- 239000003642 reactive oxygen metabolite Substances 0.000 description 7
- 108091092562 ribozyme Proteins 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 6
- 230000003143 atherosclerotic effect Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 210000004165 myocardium Anatomy 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 238000011285 therapeutic regimen Methods 0.000 description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 5
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 description 5
- 102100030416 Stromelysin-1 Human genes 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000004900 autophagic degradation Effects 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000001146 hypoxic effect Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 101150041530 ldha gene Proteins 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 210000000135 megakaryocyte-erythroid progenitor cell Anatomy 0.000 description 5
- 210000003470 mitochondria Anatomy 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 5
- 230000003827 upregulation Effects 0.000 description 5
- IERHLVCPSMICTF-XVFCMESISA-N CMP group Chemical group P(=O)(O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C(=O)N=C(N)C=C1)O)O IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 206010061216 Infarction Diseases 0.000 description 4
- 108010053763 Pyruvate Carboxylase Proteins 0.000 description 4
- 102100039895 Pyruvate carboxylase, mitochondrial Human genes 0.000 description 4
- 210000000709 aorta Anatomy 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000000453 cell autonomous effect Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 239000013317 conjugated microporous polymer Substances 0.000 description 4
- 230000001351 cycling effect Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000011132 hemopoiesis Effects 0.000 description 4
- 230000007574 infarction Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000001700 mitochondrial membrane Anatomy 0.000 description 4
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- QUTFFEUUGHUPQC-ILWYWAAHSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC1=CC=C([N+]([O-])=O)C2=NON=C12 QUTFFEUUGHUPQC-ILWYWAAHSA-N 0.000 description 3
- VRYALKFFQXWPIH-GVQCHKFTSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C[14CH]=O VRYALKFFQXWPIH-GVQCHKFTSA-N 0.000 description 3
- 101150037123 APOE gene Proteins 0.000 description 3
- 150000000780 D-glucose derivatives Chemical class 0.000 description 3
- 101100216294 Danio rerio apoeb gene Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229940124226 Farnesyltransferase inhibitor Drugs 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 101100396742 Homo sapiens IL3RA gene Proteins 0.000 description 3
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 108090000340 Transaminases Proteins 0.000 description 3
- 102000003929 Transaminases Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 3
- 239000000074 antisense oligonucleotide Substances 0.000 description 3
- 238000012230 antisense oligonucleotides Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000013170 computed tomography imaging Methods 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 3
- 230000034659 glycolysis Effects 0.000 description 3
- 239000000122 growth hormone Substances 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000000260 hypercholesteremic effect Effects 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000005565 malate-aspartate shuttle Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000010627 oxidative phosphorylation Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 230000003393 splenic effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- DEPMSUUWSGUYKQ-IWXIMVSXSA-N (2r,3s,4r,5r)-2,3,4,5-tetrahydroxy-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanal Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CNC1=CC=C([N+]([O-])=O)C2=NON=C12 DEPMSUUWSGUYKQ-IWXIMVSXSA-N 0.000 description 2
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 description 2
- IJFXRHURBJZNAO-UHFFFAOYSA-N 3-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC(O)=C1 IJFXRHURBJZNAO-UHFFFAOYSA-N 0.000 description 2
- WBLZUCOIBUDNBV-UHFFFAOYSA-N 3-nitropropanoic acid Chemical compound OC(=O)CC[N+]([O-])=O WBLZUCOIBUDNBV-UHFFFAOYSA-N 0.000 description 2
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 2
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 2
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 2
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 108010018763 Biotin carboxylase Proteins 0.000 description 2
- 101100450705 Caenorhabditis elegans hif-1 gene Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 238000000116 DAPI staining Methods 0.000 description 2
- 206010014950 Eosinophilia Diseases 0.000 description 2
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 108091052347 Glucose transporter family Proteins 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010027906 Monocytosis Diseases 0.000 description 2
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 2
- 206010029379 Neutrophilia Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 102100038803 Somatotropin Human genes 0.000 description 2
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 2
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- FRSWCCBXIHFKKY-UHFFFAOYSA-N [3-fluoro-2-(3-hydroxybenzoyl)oxyphenyl] 3-hydroxybenzoate Chemical compound OC1=CC=CC(C(=O)OC=2C(=C(F)C=CC=2)OC(=O)C=2C=C(O)C=CC=2)=C1 FRSWCCBXIHFKKY-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000004908 autophagic flux Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000002616 endonucleolytic effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- -1 for example Chemical class 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 150000002303 glucose derivatives Chemical class 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 238000011194 good manufacturing practice Methods 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 229940049920 malate Drugs 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- 230000006705 mitochondrial oxidative phosphorylation Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 238000005895 oxidative decarboxylation reaction Methods 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000012660 pharmacological inhibitor Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- CZRCFAOMWRAFIC-UHFFFAOYSA-N 5-(tetradecyloxy)-2-furoic acid Chemical compound CCCCCCCCCCCCCCOC1=CC=C(C(O)=O)O1 CZRCFAOMWRAFIC-UHFFFAOYSA-N 0.000 description 1
- MPLLLQUZNJSVTK-UHFFFAOYSA-N 5-[3-[4-[2-(4-fluorophenyl)ethoxy]phenyl]propyl]furan-2-carboxylic acid Chemical compound O1C(C(=O)O)=CC=C1CCCC(C=C1)=CC=C1OCCC1=CC=C(F)C=C1 MPLLLQUZNJSVTK-UHFFFAOYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 102100036608 Aspartate aminotransferase, cytoplasmic Human genes 0.000 description 1
- 102100034193 Aspartate aminotransferase, mitochondrial Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 1
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 238000010867 Hoechst staining Methods 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000929698 Homo sapiens Aspartate aminotransferase, cytoplasmic Proteins 0.000 description 1
- 101000799549 Homo sapiens Aspartate aminotransferase, mitochondrial Proteins 0.000 description 1
- 101000904228 Homo sapiens Vesicle transport protein GOT1A Proteins 0.000 description 1
- 101000904204 Homo sapiens Vesicle transport protein GOT1B Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 108010028501 Hypoxia-Inducible Factor 1 Proteins 0.000 description 1
- 102000016878 Hypoxia-Inducible Factor 1 Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010036650 Immunoproteins Proteins 0.000 description 1
- 102000012214 Immunoproteins Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010038452 Interleukin-3 Receptors Proteins 0.000 description 1
- 102000010790 Interleukin-3 Receptors Human genes 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 229940121730 Janus kinase 2 inhibitor Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 102100034671 L-lactate dehydrogenase A chain Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010088350 Lactate Dehydrogenase 5 Proteins 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 241000819554 Mendis Species 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102000037054 SLC-Transporter Human genes 0.000 description 1
- 108091006207 SLC-Transporter Proteins 0.000 description 1
- 101150058068 SLC2A1 gene Proteins 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 102000037089 Uniporters Human genes 0.000 description 1
- 108091006293 Uniporters Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004103 aerobic respiration Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000002715 bioenergetic effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000009743 cell cycle entry Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- WUXHQHDSSKBJFH-DELKKKATSA-N chlorothricin Chemical compound COC1=CC=C(Cl)C(C)=C1C(=O)O[C@H]1[C@H](O)[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3[C@@H]4[C@H]([C@@]5(C(=O)OC=6C(=O)O[C@@]7(C=6O)C[C@@H](C)C(=C[C@H]7/C=C/CCCC[C@@H]5C=C4)C(O)=O)C)CCC3)C[C@H]2O)C)C1 WUXHQHDSSKBJFH-DELKKKATSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000011340 continuous therapy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000007821 culture assay Methods 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000222 eosinocyte Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000009215 host defense mechanism Effects 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 208000021156 intermittent vascular claudication Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000006674 lysosomal degradation Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- GKFPROVOIQKYTO-UZLBHIALSA-N methyl (2s)-2-[[4-[[(2r)-2-amino-3-sulfanylpropyl]amino]-2-phenylbenzoyl]amino]-4-methylsulfanylbutanoate Chemical compound CSCC[C@@H](C(=O)OC)NC(=O)C1=CC=C(NC[C@@H](N)CS)C=C1C1=CC=CC=C1 GKFPROVOIQKYTO-UZLBHIALSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000008437 mitochondrial biogenesis Effects 0.000 description 1
- 230000006540 mitochondrial respiration Effects 0.000 description 1
- 230000008811 mitochondrial respiratory chain Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 238000007491 morphometric analysis Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229950010456 pimonidazole Drugs 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Inorganic materials [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 229940080817 rotenone Drugs 0.000 description 1
- JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008718 systemic inflammatory response Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 208000008203 tachypnea Diseases 0.000 description 1
- 206010043089 tachypnoea Diseases 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000005891 transamination reaction Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000001296 transplacental effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000004143 urea cycle Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- JLYXXMFPNIAWKQ-UHFFFAOYSA-N γ Benzene hexachloride Chemical compound ClC1C(Cl)C(Cl)C(Cl)C(Cl)C1Cl JLYXXMFPNIAWKQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the invention is in the field of coronary or vascular disorders, more particularly to myelopoiesis-driven cardio metabolic diseases and sepsis.
- the present invention also relates to a pharmaceutical composition for the treatment of myelopoiesis-driven cardio metabolic diseases and sepsis.
- Atherosclerosis is a chronic, hypercholesterolemia-driven inflammatory disease that is initiated by the deposition of cholesterol-rich lipoproteins in the artery wall, leading to monocyte-macrophage recruitment.
- Hypercholesterolemia and/or defective cholesterol efflux have also been documented to induce myelopoiesis, which contributes to atherosclerotic lesion formation by fueling plaques with monocytes and neutrophils.
- the monocyte count in particular, independently predicts risk for coronary artery disease after adjustment for conventional risk factors. 3 ' 4
- Hematopoietic stem cells are quiescent in the bone marrow (BM) niche and are the source of all hematopoietic stem and multi-potential progenitors (HSPCs) and differentiated cells that are critical for the maintenance and replenishment of peripheral leukocytes in adult life, particularly during emergency hematopoiesis.
- HSPCs multi-potential progenitors
- inventors and others have recently shown that chronic cholesterol accumulation in HSPCs due to hypercholesterolemia and/or defective apo lipoprotein (Apo)-mediated cholesterol efflux promotes pathogenic HSPC expansion and proliferation leading to uncontrolled myelopoiesis.
- the present invention relates to a method of treating myelopoiesis-driven cardio metabolic diseases and sepsis in a subject in need thereof comprising the step of administrating the subject with a therapeutically effective amount of an agent selected from the group consisting of GLUT1 inhibitors and GOTs inhibitors.
- an agent selected from the group consisting of GLUT1 inhibitors and GOTs inhibitors.
- the present invention relates to a method of treating myelopoiesis-driven cardio metabolic diseases and sepsis in a subject in need thereof comprising the step of inhibiting Glutl and GOTs in said subject.
- the present invention relates to a method of treating myelopoiesis- driven cardio metabolic diseases and sepsis in a subject in need thereof comprising the step of administrating the subject with a therapeutically effective amount of an agent selected from the group consisting of GLUT1 inhibitors and GOTs inhibitors.
- treating refers to both prophylactic or preventive treatment as well as curative or disease modifying treatment, including treatment of subject at risk of contracting the disease or suspected to have contracted the disease as well as subject who are ill or have been diagnosed as suffering from a disease or medical condition, and includes suppression of clinical relapse.
- the treatment may be administered to a subject having a medical disorder or who ultimately may acquire the disorder, in order to prevent, cure, delay the onset of, reduce the severity of, or ameliorate one or more symptoms of a disorder or recurring disorder, or in order to prolong the survival of a subject beyond that expected in the absence of such treatment.
- therapeutic regimen is meant the pattern of treatment of an illness, e.g., the pattern of dosing used during therapy.
- a therapeutic regimen may include an induction regimen and a maintenance regimen.
- the phrase “induction regimen” or “induction period” refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the initial treatment of a disease.
- the general goal of an induction regimen is to provide a high level of drug to a subject during the initial period of a treatment regimen.
- An induction regimen may employ (in part or in whole) a "loading regimen", which may include administering a greater dose of the drug than a physician would employ during a maintenance regimen, administering a drug more frequently than a physician would administer the drug during a maintenance regimen, or both.
- maintenance regimen refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the maintenance of a subject during treatment of an illness, e.g., to keep the subject in remission for long periods of time (months or years).
- a maintenance regimen may employ continuous therapy (e.g., administering a drug at a regular intervals, e.g., weekly, monthly, yearly, etc.) or intermittent therapy (e.g., interrupted treatment, intermittent treatment, treatment at relapse, or treatment upon achievement of a particular predetermined criteria [e.g., pain, disease manifestation, etc.]).
- myelopoiesis-driven cardio metabolic diseases refers to myocardium infarction or chronic atherosclerosis.
- Myelopoiesis refers to a formation of myeloid cells, including eosinophilic granulocytes, basophilic granulocytes, neutrophilic granulocytes, and monocytes.
- Hypercholesterolemia and/or defective cholesterol efflux have also been documented to induce myelopoiesis, which contributes to atherosclerotic lesion formation by fueling plaques with monocytes and neutrophils.
- MI Myocardium infarction
- Atherosclerosis is a chronic, hypercholesterolemia-driven inflammatory disease that is initiated by the deposition of cholesterol-rich lipoproteins in the artery wall, leading to monocyte-macrophage recruitment.
- Atherosclerosis contributes to the development of atherosclerotic vascular diseases (AVD) which may affect the coronary arteries (causing ischaemic heart disease), the cerebral circulation (causing cerebrovascular disease), the aorta (producing aneurysms that are prone to thrombosis and rupture) and peripheral blood vessels, typically the legs (causing peripheral vascular disease and intermittent claudication).
- Ischaemic heart disease (IHD) includes angina (chest pain caused by insufficient blood supply to cardiac muscle) and myocardial infarction (death of cardiac muscle) and cerebrovascular disease includes stroke and transient ischaemic attacks.
- Sepsis is a systemic reaction characterized by arterial hypotension, metabolic acidosis, decreased systemic vascular resistance, tachypnea and organ dysfunction. Sepsis (including septic shock) is characterized by a systemic inflammatory response which results from the activation of a number of host defense mechanisms including the release of cytokines, the activation of immune cells, the complement system and the coagulation pathway.
- the method according to the present invention can be supplied to a subject, who has been diagnosed as presenting one of the following myelopoiesis-driven cardio metabolic driven diseases: myocardium infarction or chronic atherosclerosis.
- the method according to the present invention wherein the myelopoiesis-driven cardio metabolic disease is atherosclerosis.
- the method of the present invention can also be supplied to a subject who has been diagnosed for sepsis.
- subject refers to any mammals, such as a rodent, a feline, a canine, and a primate.
- the subject is a human afflicted with or susceptible to be afflicted with myelopoiesis-driven diseases.
- the subject is a human afflicted or susceptible to be afflicted with atherosclerosis.
- agent selected from the group consisting of GLUT1 inhibitors and GOTs inhibitors refers to the capacity of any compound to reduce or inhibit Glutl cell surface expression or GOTs, particularly Glutl expression or GOTs in HSPCs and myeloid cells. Inhibition includes reduction of function and full blockade.
- Glucose transporter 1 also known as solute carrier family 2 or facilitated glucose transporter member 1 (SLC2A1), is a uniporter protein that in humans is encoded by the SLC2A1 gene.
- GLUT1 facilitates the transport of glucose across the plasma membranes of mammalian cells, particularly facilitates the entry of D-glucose across the blood-barrier brain.
- Glutamate oxaloacetate transaminases are pyridoxal phosphate-dependent enzymes which exist in cytoplasmic and mitochondrial forms, GOT1 and GOT2, respectively. GOTs play a role in amino acid metabolism and the urea and tricarboxylic acid cycles. The two enzymes are homodimeric and show close homology.
- the inhibitors of GLUT1 could be an antibody, synthetic or native sequence peptides, small molecules or aptamers.
- the inhibitor of Glutl is a small organic molecule.
- small organic molecule refers to a molecule of a size comparable to those organic molecules generally used in pharmaceuticals.
- small organic molecules range in size up to about 5000 Da, more preferably up to 2000 Da, and most preferably up to about 1000 Da.
- the inhibitor of Glutl is a small organic molecule such as described in WO2011119866, WO2013182612, WO2015112581, Wood et al 2008, Amann et al 2009, Liu et al 2012, Qian et al 2014 and Shibuya et al 2014.
- the inhibitor of Glutl is WZB117, also called 3-Fluoro- 1 ,2-phenylene bis(3-hydroxybenzoate), 3-Hydroxy-benzoic acid 1,1 ' -(3-fluoro-l,2- phenylene) ester and has the following formula in the art:
- the inhibitor of Glutl is Fasentin, also called N-[4-Chloro- 3-(trifluoromethyl)phenyl]-3-oxobutanamide and has the followin formula in the art:
- the inhibitor of Glutl is a plant carbohydrate product such as Astragalin-6-glucoside such as described in Thom son et al 2015.
- the inhibitor of Glutl is genistein, also called 5,7- dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one and has the following formula in the art:
- the inhibitor of GLUT1 is an antibody.
- antibody is used in the broadest sense and specifically covers monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g. bispecific antibodies) formed from at least two intact antibodies, and antibody fragments so long as they exhibit the desired biological activity.
- two heavy chains are linked to each other by disulfide bonds and each heavy chain is linked to a light chain by a disulfide bond.
- light chain There are two types of light chain, lambda (1) and kappa (k).
- Each chain contains distinct sequence domains.
- the light chain includes two domains, a variable domain (VL) and a constant domain (CL).
- the heavy chain includes four domains, a variable domain (VH) and three constant domains (CHI, CH2 and CH3, collectively referred to as CH).
- the variable regions of both light (VL) and heavy (VH) chains determine binding recognition and specificity to the antigen.
- the constant region domains of the light (CL) and heavy (CH) chains confer important biological properties such as antibody chain association, secretion, trans-placental mobility, complement binding, and binding to Fc receptors (FcR).
- the term includes antibody fragments that comprise an antigen binding domain such as Fab', Fab, F(ab')2, single domain antibodies (DABs), TandAbs dimer, Fv, scFv (single chain Fv), dsFv, ds-scFv, Fd, linear antibodies, minibodies, diabodies, bispecific antibody fragments, bibody, tribody (scFv-Fab fusions, bispecific or trispecific, respectively); sc-diabody; kappa(lamda) bodies (scFv-CL fusions); BiTE (Bispecific T-cell Engager, scFv-scFv tandems to attract T cells); DVD-Ig (dual variable domain antibody, bispecific format); SIP (small immunoprotein, a kind of minibody); SMIP ("small modular immunopharmaceutical” scFv-Fc dimer; DART (ds-stabilized diabody "Dual Affinity ReTargeting"
- Antibodies can be fragmented using conventional techniques. For example, F(ab')2 fragments can be generated by treating the antibody with pepsin. The resulting F(ab')2 fragment can be treated to reduce disulfide bridges to produce Fab' fragments. Papain digestion can lead to the formation of Fab fragments.
- Fab, Fab' and F(ab')2, scFv, Fv, dsFv, Fd, dAbs, TandAbs, ds-scFv, dimers, minibodies, diabodies, bispecific antibody fragments and other fragments can also be synthesized by recombinant techniques or can be chemically synthesized. Techniques for producing antibody fragments are well known and described in the art. For example, each of Beckman et al, 2006; Holliger & Hudson, 2005; Le Gall et al, 2004; Reff & Heard, 2001 ; Reiter et al, 1996; and Young et al, 1995 further describe and enable the production of effective antibody fragments.
- the antibody is a "chimeric" antibody as described in U.S. Pat. No. 4,816,567.
- the antibody is a humanized antibody, such as described U.S. Pat. Nos. 6,982,321 and 7,087,409.
- the antibody is a human antibody.
- a "human antibody” such as described in US 6,075,181 and 6,150,584.
- the antibody is a single domain antibody such as described in EP 0 368 684, WO 06/030220 and WO 06/003388.
- the inhibitor of Glutl is a monoclonal antibody.
- Monoclonal antibodies can be prepared and isolated using any technique that provides for the production of antibody molecules by continuous cell lines in culture.
- Techniques for production and isolation include but are not limited to the hybridoma technique, the human B-cell hybridoma technique and the EBV- hybridoma technique.
- the inhibitor of GOTs belongs to the aminooxyacetic acid
- AO A 2-(aminooxy) acetic acid
- the inhibitor of Glutl or GOTs is an inhibitor of GLUT1 or GOTs expression.
- an “inhibitor of GLUT1 or GOTs expression” refers to a natural or synthetic compound that has a biological effect to inhibit or significantly reduce the expression of the gene encoding for GLUT1 or GOTs.
- the inhibitor of GLUT1 or GOTs expression has a biological effect on one or more of the following events: (1) production of an RNA template from a DNA sequence (e.g., by transcription); (2) processing of an RNA transcript (e.g., by splicing, editing, 5' cap formation, and/or 3' end formation); (3) translation of an RNA into a polypeptide or protein; and/or (4) post-translational modification of a polypeptide or protein.
- the inhibitor of GLUT1 or GOTs expression is an antisense oligonucleotide.
- Anti-sense oligonucleotides including anti-sense RNA molecules and anti- sense DNA molecules, would act to directly block the translation of GLUT1 mRNA or GOTs mRNA by binding thereto and thus preventing protein translation or increasing mRNA degradation, thus decreasing the level of GLUT1 or GOTs proteins, and thus activity, in a cell.
- antisense oligonucleotides of at least about 15 bases and complementary to unique regions of the mRNA transcript sequence encoding GLUT1 or GOTs can be synthesized, e.g., by conventional phosphodiester techniques and administered by e.g., intravenous injection or infusion.
- Methods for using antisense techniques for specifically alleviating gene expression of genes whose sequence is known are well known in the art (e.g. see U.S. Pat. Nos. 6,566,135; 6,566,131; 6,365,354; 6,410,323; 6,107,091; 6,046,321; and 5,981,732).
- the inhibitor of GLUT1 or GOTs expression is a small inhibitory RNAs (siRNAs).
- GLUT1 or GOTs expression can be reduced by contacting the subject or cell with a small double stranded RNA (dsRNA), or a vector or construct causing the production of a small double stranded RNA, such that GLUT1 or GOTs expression is specifically inhibited (i.e. RNA interference or RNAi).
- dsRNA small double stranded RNA
- RNAi RNA interference
- Methods for selecting an appropriate dsRNA or dsRNA-encoding vector are well known in the art for genes whose sequence is known (e.g. see Tuschl, T. et al. (1999); Elbashir, S. M. et al. (2001); Hannon, GJ.
- inhibitor of GLUT1 or GOTs expression is ribozyme.
- Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA.
- the mechanism of ribozyme action involves sequence specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleo lytic cleavage.
- Engineered hairpin or hammerhead motif ribozyme molecules that specifically and efficiently catalyze endonucleo lytic cleavage of GLUT1 or GOTs mRNA sequences are thereby useful within the scope of the present invention.
- Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, which typically include the following sequences, GUA, GUU, and GUC.
- RNA sequences of between about 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site can be evaluated for predicted structural features, such as secondary structure, that can render the oligonucleotide sequence unsuitable.
- the suitability of candidate targets can also be evaluated by testing their accessibility to hybridization with complementary oligonucleotides, using, e.g., ribonuclease protection assays.
- a "therapeutically effective amount" is intended for a minimal amount of active agent which is necessary to impart therapeutic benefit to a subject.
- a "therapeutically effective amount" to a subject is such an amount which induces, ameliorates or otherwise causes an improvement in the pathological symptoms, disease progression or physiological conditions associated with or resistance to succumbing to a disorder. It will be understood that the total daily usage of the compounds of the present invention will be decided by the attending physician within the scope of sound medical judgment.
- the specific therapeutically effective dose level for any particular subject will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific composition employed, the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidential with the specific compound employed; and like factors well known in the medical arts.
- the daily dosage of the products may be varied over a wide range from 0.01 to 1,000 mg per adult per day.
- the compositions contain 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 250 and 500 mg of the active ingredient for the symptomatic adjustment of the dosage to the subject to be treated.
- a medicament typically contains from about 0.01 mg to about 500 mg of the active ingredient, preferably from 1 mg to about 100 mg of the active ingredient.
- An effective amount of the drug is ordinarily supplied at a dosage level from 0.0002 mg/kg to about 20 mg/kg of body weight per day, especially from about 0.001 mg/kg to 7 mg/kg of body weight per day.
- GLUT1 inhibitors and GOTs inhibitors as described above may be combined with pharmaceutically acceptable excipients, and optionally sustained-release matrices, such as biodegradable polymers, to form pharmaceutical compositions.
- pharmaceutically acceptable excipients such as a carboxylate, a carboxylate, a carboxylate, a carboxylate, a carboxylate, a carboxylate, a carboxylate, a carboxylate, a pharmaceutically acceptable.
- pharmaceutically acceptable carrier or excipient refers to a non-toxic solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
- compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, transdermal, local or rectal administration can be administered in a unit administration form, as a mixture with conventional pharmaceutical supports, to animals and human beings.
- Suitable unit administration forms comprise oral- route forms such as tablets, gel capsules, powders, granules and oral suspensions or solutions, sublingual and buccal administration forms, aerosols, implants, subcutaneous, transdermal, topical, intraperitoneal, intramuscular, intravenous, subdermal, transdermal, intrathecal and intranasal administration forms and rectal administration forms.
- the pharmaceutical compositions contain vehicles which are pharmaceutically acceptable for a formulation capable of being injected.
- vehicles which are pharmaceutically acceptable for a formulation capable of being injected.
- These may be in particular isotonic, sterile, saline solutions (monosodium or disodium phosphate, sodium, potassium, calcium or magnesium chloride and the like or mixtures of such salts), or dry, especially freeze-dried compositions which upon addition, depending on the case, of sterilized water or physiological saline, permit the constitution of injectable solutions.
- the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions; formulations including sesame oil, peanut oil or aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
- the form In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
- Solutions comprising compounds of the invention as free base or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
- the polypeptide (or nucleic acid encoding thereof) can be formulated into a composition in a neutral or salt form.
- Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.
- the carrier can also be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetables oils.
- the proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
- isotonic agents for example, sugars or sodium chloride.
- Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminium monostearate and gelatin.
- Sterile injectable solutions are prepared by incorporating the active polypeptides in the required amount in the appropriate solvent with several of the other ingredients enumerated above, as required, followed by filtered sterilization.
- dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
- sterile powders for the preparation of sterile injectable solutions
- the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile- filtered solution thereof.
- solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective.
- the formulations are easily administered in a variety of dosage forms, such as the type of injectable solutions described above, but drug release capsules and the like can also be employed.
- parenteral administration in an aqueous solution for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
- aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.
- sterile aqueous media which can be employed will be known to those of skill in the art in light of the present disclosure.
- one dosage could be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion. Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.
- FIGURES
- FIG. 1 Enhanced glucose utilization in the aortic arch, splenocytes, BM and HSPCs of ApoE' ' BM chimeras.
- A 2-deoxy-[ 14 C] -glucose uptake in aortic arch, bone marrow and spleen of ApoE ' '' ' recipients transplanted with WT or ApoE '1' BM at 12 weeks after the transplantation procedure.
- MMP mitochondrial membrane potential
- TMRE fluorescent tetramethylrhodamine ethyl ester
- Lin Lineage marker
- Lin + and CD34 CD34 + HSPCs isolated from the BM of these mice.
- E NBD-glucose binding and/or uptake and
- F cell surface expression of Glutl was also quantified in these cells. All results are the means ⁇ SEM and are representative of at least one experiment performed with 6-10 animals per group. *P ⁇ 0.05 vs. WT. ⁇ ⁇ 0.05 vs. the untreated condition.
- FIG. 1 HIFla-independent regulation of Glutl expression and ApoE-/- HSPC expansion and myeloid lineage fate.
- A Experimental overview. Bone marrow from Mxl- Cre (controls), Mxl-cre HIFl D fi/fi, ApoE-/- Mxl-Cre, ApoE-/- Mxl-cre HIFl D fi/fl mice were transplanted into ApoE-/- recipient mice and, after a 5 week recovery period, the mice were injected with PolyTC and fed a high fat diet for 12 weeks to induce the expansion of HSPCs.
- B Representative Western blots showing HIFl ⁇ levels in BM cells freshly isolated from these mice at the end of the study period.
- Quantification (normalized to ⁇ -actin) is expressed as arbitrary unit and indicated by numbers below (C) mRNA expression of HIFl ⁇ and HIF1 D target genes Ldha and Glutl in BM cells freshly isolated from these mice at the end of the study period. (D) Histograms showing Glutl cell surface expression (expressed as the mean fluorescence intensity (MFI)) in CD34- and CD34+ HSPCs. (E) Quantification of the CD34- or CD34+ HSPCs by flow cytometry was expressed as the percentage of total BM. (F) peripheral blood neutrophils, monocytes and eosinophils were also quantified in these mice at the end of the study period. The results are the means ⁇ SEM of 6-10 animals per group. *P ⁇ 0.05 vs. Mxl-Cre. ⁇ P ⁇ 0.05 vs. ApoE-/- Mxl-Cre.
- FIG. 3 The ApoE A HSPC expansion and myeloid lineage fate and Glutl upregulation are driven by the IL3R signaling pathway.
- A Twenty- week-old WT and ApoE ' '' ' mice were injected with IgG control or 100 ⁇ g of the IL-3RP blocking antibody for 24 h and analyzed for peripheral blood myeloid cells by flow cytometry.
- B The CD34 " or CD34 + HSPCs were quantified in the BM of these mice and was expressed as the percentage of total BM.
- C The percentage of these cells in S/G2M phase was determined by Hoechst staining, and
- D Glutl cell surface expression was expressed as the mean fluorescence intensity (MFI). The results are the means ⁇ SEM of 5 to 6 animals per group. *P ⁇ 0.05 vs. WT IgG control. ⁇ ⁇ 0.05 vs. ApoE '1' IgG control.
- FIG. 4 Mitochondrial glycolytic substrate utilization is required for ApoE-/- HSPC proliferation and myelomonyctic fate in vitro.
- Bone marrow cells from fluorouracil-treated WT and ApoE-/- mice were grown for 72h in liquid culture containing 10% FBS IMDM in the presence of the indicated chemical compounds and 6ng/mL IL-3 or 2ng/mL GM-CSF.
- Glutl is required in vitro for the IL3R -dependent ApoE' ' HSPC expansion and myeloid lineage fate. Bone marrow cells from WT, Glutl +/ ⁇ , ApoE '11' , and
- ApoE ⁇ / ⁇ Glutl +/ ⁇ mice were sorted for Lin " cells (i.e, enriched in HSPCs) and cultured for 72h in liquid culture in presence or absence of 6ng/mL IL-3 or 2ng/mL GM-CSF.
- A Representative dot plots and (B) quantification of HSPCs after in vitro culture.
- C Representative dot plots and (D) quantification of CDl lb + Gr-l + myeloid cells after in vitro culture.
- E Quantification of ROS generation and (F) mitochondrial membrane potential (MMP) by flow cytometry using fluorescent carboxy-H 2 DCFDA and tetramethylrhodamine ethyl ester (TMRE) dyes, respectively in HSPCs after in vitro culture.
- TMRE mitochondrial membrane potential
- FIG. 6 Glutl-dependence of ApoE-/- HSPC expansion and myelopoiesis in vivo.
- A Experimental overview. Bone marrow from WT, Glutl +/-, ApoE-/-, and ApoE-/- Glutl +/- mice were transplanted into ApoE-/- recipient mice and, after a 5 week recovery period, the mice were fed a high fat diet for 12 weeks to induce the expansion of HSPCs.
- Histograms show (B) the Glutl cell surface expression and (C) NBD-glucose binding and/or uptake in HSPC subpopulations from the most quiescent (long-term LT-HSCs) to the most cycling multipotential progenitors (CD34-CD150+Flt3->CD34+CD150+Flt3- >CD34+CD150-Flt3->CD34+CD150-Flt3+) and are expressed as the mean fluorescence intensity (MFI).
- MFI mean fluorescence intensity
- D The percentage of cells in S/G2M phase was determined by DAPI staining and flow cytometry, and (E) quantified as the percentage of total BM.
- GMP granulocyte macrophage progenitor
- CMP common myeloid progenitor
- MEP megakaryocyte-erythroid progenitor
- FIG. 7 Cell autonomous role of Glutl on ApoE ⁇ A HSPC expansion and myeloid lineage commitment.
- Schematic diagram showing the protocol for the competitive repopulation assay. Equally mixed portions of BM from the respective genotypes were transplanted into WT recipients. Chow- fed recipient mice were analyzed at 10 weeks after reconstitution by flow cytometry for the contribution of the donor (CD45.1 + /CD45.2 + ) to the HSPC subpopulations from the most quiescent (long-term LT-HSCs) to the most cycling multipotential progenitors (CD34 CD150 + >CD34 + CD150 + > CD34 + CD150 " ) in the bone marrow.
- FIG. 8 Glutl deficiency reduces the accelerated atherosclerosis of ApoE ⁇ A BM chimeras.
- the values for individual mice are shown as open circles, representing an average of 6 sections per mouse.
- the horizontal bars represent the group medians.
- the macrophages were detected by F4/80 immuno fluorescent staining in the proximal aorta and quantified as the mean intensity (magnification, X200). Aortic arch and spleen uptake of 2-deoxy-[ 14 C] -glucose in these mice at the end of the study period. All results are the means ⁇ SEM and are representative of 10 to 12 animals per group. ⁇ ⁇ 0.05 vs. ApoE '1' mice receiving ApoE '1' BM.
- the enhanced glucose uptake in atheromatous plaques under hypercholesterolemic conditions correlates with higher metabolic activity of hematopoietic cells and is associated with higher Glutl expression in HSPCs.
- To monitor the metabolic activity of hematopoietic cells we first investigated the uptake of the radiolabeled D-glucose analogue 2-deoxy [14C] glucose in organs isolated from irradiated ApoE-/- recipient mice transplanted with either WT or ApoE-/- bone marrow (BM).
- HIFla is neither involved in the up-regulation of Glutl in ApoE-/- HSPCs nor the enhanced myelopoiesis of ApoE-/- mice.
- HIFla is neither involved in the up-regulation of Glutl in ApoE-/- HSPCs nor the enhanced myelopoiesis of ApoE-/- mice.
- hypoxia inducible factor 1 ⁇ up-regulates Glut 1,37 and HIF1 ⁇ contributes to HSPC homeostasis.18,20
- FITC fluorescein-conjugated anti-Pimonidazole
- HIF I D protein was also barely detectable in WT and ApoE-/- BM cell lysates under normoxic culture conditions and cell lysates from ApoE-/- BM cells showed amounts of HIF I D protein similar to those of WT cells under hypoxia (Supplemental Fig. 1A).
- HFD high fat diet
- PIpC polykpolylC
- HIF1 ⁇ deficiency also did not alter the cell surface expression of Glutl in CD34+ HSPCs and CD34- LT-HSCs (Fig. 2D) or the frequency of these cells (Fig. 2E). Furthermore, quantification of the blood myeloid cells in these mice revealed that HIF1 ⁇ deficiency further increased the neutrophil, monocyte and eosinophil counts in these mice (Fig. 2F). Together, these findings suggest that HIF1 ⁇ does not mediate the upregulation of Glutl in ApoE-/- HSPC or their expansion and minimally contributed to myelopoiesis under hypercholesterolemic conditions.
- the IL-3RJ5 signaling pathway concomitantly controls the cycling and the upregulation of Glutl in ApoE-/- HSPCs.
- Glutl can be up-regulated by growth hormone-dependent activation of oncogenes, such as Ras or Src.38,39 Therefore, we investigated the expression of Glutl in WT and ApoE-/- BM cultures in response to various growth hormones.
- the Glutl mRNA levels in WT BM cells were increased upon stimulation with GM-CSF and IL-3, but not Flt3L or TPO, and this response was further increased in the ApoE-/- BM cells and blunted by a farnesyl transferase inhibitor that blocks Ras activation (Supplemental Fig.
- Glutl deficiency prevented the reduced Cyto-ID staining induced by IL-3 in HSPCs isolated from WT Lin- cultures and restored the autophagic flux of ApoE-/- HSPCs to the level of control cells (Supplemental Fig. 2E and 2F).
- the Glutl cell surface expression was decreased by an approximately 1.4-fold in the MMP2 of mice receiving either Glutl+/- or ApoE-/-Glutl+/- BM (Fig. 6B and Supplemental Fig. 3D). This confirmed the efficiency of the transplantation procedure.
- the 2-NBDG staining quantified by flow cytometry suggested Glutl - independent glucose utilization in different populations within the HSPCs, but confirmed an approximately 1.35-fold decrease in 2-NBDG staining in the CD34+CD150+Flt3- MMP2 of mice receiving either Glutl+/- or ApoE-/-Glutl+/- BM compared to their respective controls (Fig. 6C and Supplemental Fig.
- CMP common myeloid progenitor
- GMP granulocyte macrophage progenitor
- MEP megakaryocyte-erythroid progenitor
- Glutl acts in a cell-autonomous fashion to regulate ApoE-/- HSPC proliferation and myelopoiesis.
- this phenotype was caused by cell autonomous effects of Glutl within the my elo id-biased HSPCs or involved a cell extrinsic effect.
- we performed a competitive BM transplantation experiment with equally mixed BM cells from CD45.1 ApoE-/- mice and either CD45.2 ApoE-/- BM or CD45.2 ApoE-/-Glutl+/ BM into irradiated WT recipients.
- Glutl deficiency prevents the progression of atherosclerosis in ApoE-/- BM- transplanted mice.
- the body weight, plasma LDL and HDL cholesterol or plasma glucose were not significantly different with regard to Glutl deficiency.
- the metabolic phenotype of ApoE '1' HSPCs outlined here could be relevant to the adaptability of HSPCs to cholesterol overload and may indicate that the glycolytic phenotype of HSPCs is not merely a product of their hypoxic environment.
- the existence of different molecular mechanisms underlying the different glycolytic phenotypes in HSPCs may suggest strategies for specifically modulating the pool of HSPCs that are committed to the myeloid lineage under stressed conditions, such as in myeloproliferative disorders, 36 sepsis, 53 myocardium infarction, 54 or chronic atherosclerosis, as shown in the present study.
- Inhibition of glucose uptake by a Glutl inhibitor that does not cross the blood-brain barrier could ultimately provide a novel therapeutic approach to prevent myelopoiesis-driven diseases such as atherosclerosis.
- Drechsler M Megens RTA, van Zandvoort M, Weber C, Soehnlein O. Hyperlipidemai-triggered neutrophilia promotes early atherosclerosis/clinical perspectives.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne une méthode permettant de traiter la septicémie et les maladies induites par la myélopoïèse chez un sujet en ayant besoin, comprenant l'administration au sujet d'une quantité thérapeutiquement efficace d'un agent sélectionné dans le groupe constitué d'inhibiteurs de GLUT1 et d'inhibiteurs de GOTs.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16305067 | 2016-01-25 | ||
EP16305067.7 | 2016-01-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017129558A1 true WO2017129558A1 (fr) | 2017-08-03 |
Family
ID=55237616
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2017/051418 WO2017129558A1 (fr) | 2016-01-25 | 2017-01-24 | Méthodes permettant de prévoir ou de traiter la septicémie et les maladies cardiométaboliques induites par la myélopoïèse |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2017129558A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114751854A (zh) * | 2022-03-23 | 2022-07-15 | 中国科学院自动化研究所 | 近红外荧光探针及其制备方法和应用 |
Citations (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
EP0368684A1 (fr) | 1988-11-11 | 1990-05-16 | Medical Research Council | Clonage de séquences d'immunoglobulines de domaines variables. |
EP0404097A2 (fr) | 1989-06-22 | 1990-12-27 | BEHRINGWERKE Aktiengesellschaft | Récepteurs mono- et oligovalents, bispécifiques et oligospécifiques, ainsi que leur production et application |
WO1993011161A1 (fr) | 1991-11-25 | 1993-06-10 | Enzon, Inc. | Proteines multivalentes de fixation aux antigenes |
WO1999032619A1 (fr) | 1997-12-23 | 1999-07-01 | The Carnegie Institution Of Washington | Inhibition genetique par de l'arn double brin |
US5981732A (en) | 1998-12-04 | 1999-11-09 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-13 expression |
US6046321A (en) | 1999-04-09 | 2000-04-04 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-i1 expression |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6107091A (en) | 1998-12-03 | 2000-08-22 | Isis Pharmaceuticals Inc. | Antisense inhibition of G-alpha-16 expression |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO2001036646A1 (fr) | 1999-11-19 | 2001-05-25 | Cancer Research Ventures Limited | Inhibition d"expression genique a l"aide d"arn bicatenaire |
WO2001068836A2 (fr) | 2000-03-16 | 2001-09-20 | Genetica, Inc. | Procedes et compositions d'interference d'arn |
US6365354B1 (en) | 2000-07-31 | 2002-04-02 | Isis Pharmaceuticals, Inc. | Antisense modulation of lysophospholipase I expression |
US6410323B1 (en) | 1999-08-31 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense modulation of human Rho family gene expression |
US6566135B1 (en) | 2000-10-04 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of caspase 6 expression |
US6566131B1 (en) | 2000-10-04 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of Smad6 expression |
US6573099B2 (en) | 1998-03-20 | 2003-06-03 | Benitec Australia, Ltd. | Genetic constructs for delaying or repressing the expression of a target gene |
US6982321B2 (en) | 1986-03-27 | 2006-01-03 | Medical Research Council | Altered antibodies |
WO2006003388A2 (fr) | 2004-06-30 | 2006-01-12 | Domantis Limited | Compositions et procedes pour le traitement de troubles inflammatoires |
WO2006030220A1 (fr) | 2004-09-17 | 2006-03-23 | Domantis Limited | Compositions monovalentes pour la liaison au cd40l et procedes d'utilisation |
US7087409B2 (en) | 1997-12-05 | 2006-08-08 | The Scripps Research Institute | Humanization of murine antibody |
WO2011119866A1 (fr) | 2010-03-24 | 2011-09-29 | Ohio University | Compositions et procédés pour l'inhibition du transport du glucose |
WO2013182612A1 (fr) | 2012-06-07 | 2013-12-12 | Bayer Pharma Aktiengesellschaft | Inhibiteurs de transport du glucose |
US20140314740A1 (en) * | 2011-12-09 | 2014-10-23 | The Johns Hopkins University | Compositions and methods for the prevention or treatment of diabetic complications |
WO2015112581A1 (fr) | 2014-01-21 | 2015-07-30 | The Medical College Of Wisconsin, Inc. | Procédés d'inhibition sélective de cellules souches pluripotentes |
-
2017
- 2017-01-24 WO PCT/EP2017/051418 patent/WO2017129558A1/fr active Application Filing
Patent Citations (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6982321B2 (en) | 1986-03-27 | 2006-01-03 | Medical Research Council | Altered antibodies |
EP0368684A1 (fr) | 1988-11-11 | 1990-05-16 | Medical Research Council | Clonage de séquences d'immunoglobulines de domaines variables. |
EP0404097A2 (fr) | 1989-06-22 | 1990-12-27 | BEHRINGWERKE Aktiengesellschaft | Récepteurs mono- et oligovalents, bispécifiques et oligospécifiques, ainsi que leur production et application |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1993011161A1 (fr) | 1991-11-25 | 1993-06-10 | Enzon, Inc. | Proteines multivalentes de fixation aux antigenes |
US7087409B2 (en) | 1997-12-05 | 2006-08-08 | The Scripps Research Institute | Humanization of murine antibody |
WO1999032619A1 (fr) | 1997-12-23 | 1999-07-01 | The Carnegie Institution Of Washington | Inhibition genetique par de l'arn double brin |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
US6573099B2 (en) | 1998-03-20 | 2003-06-03 | Benitec Australia, Ltd. | Genetic constructs for delaying or repressing the expression of a target gene |
US6107091A (en) | 1998-12-03 | 2000-08-22 | Isis Pharmaceuticals Inc. | Antisense inhibition of G-alpha-16 expression |
US5981732A (en) | 1998-12-04 | 1999-11-09 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-13 expression |
US6046321A (en) | 1999-04-09 | 2000-04-04 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-i1 expression |
US6410323B1 (en) | 1999-08-31 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense modulation of human Rho family gene expression |
WO2001036646A1 (fr) | 1999-11-19 | 2001-05-25 | Cancer Research Ventures Limited | Inhibition d"expression genique a l"aide d"arn bicatenaire |
WO2001068836A2 (fr) | 2000-03-16 | 2001-09-20 | Genetica, Inc. | Procedes et compositions d'interference d'arn |
US6365354B1 (en) | 2000-07-31 | 2002-04-02 | Isis Pharmaceuticals, Inc. | Antisense modulation of lysophospholipase I expression |
US6566135B1 (en) | 2000-10-04 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of caspase 6 expression |
US6566131B1 (en) | 2000-10-04 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of Smad6 expression |
WO2006003388A2 (fr) | 2004-06-30 | 2006-01-12 | Domantis Limited | Compositions et procedes pour le traitement de troubles inflammatoires |
WO2006030220A1 (fr) | 2004-09-17 | 2006-03-23 | Domantis Limited | Compositions monovalentes pour la liaison au cd40l et procedes d'utilisation |
WO2011119866A1 (fr) | 2010-03-24 | 2011-09-29 | Ohio University | Compositions et procédés pour l'inhibition du transport du glucose |
US20140314740A1 (en) * | 2011-12-09 | 2014-10-23 | The Johns Hopkins University | Compositions and methods for the prevention or treatment of diabetic complications |
WO2013182612A1 (fr) | 2012-06-07 | 2013-12-12 | Bayer Pharma Aktiengesellschaft | Inhibiteurs de transport du glucose |
WO2015112581A1 (fr) | 2014-01-21 | 2015-07-30 | The Medical College Of Wisconsin, Inc. | Procédés d'inhibition sélective de cellules souches pluripotentes |
Non-Patent Citations (58)
Title |
---|
ANUP SRIVASTAVA ET AL: "PKM2 regulates the Warburg effect and promotes HMGB1 release in sepsis", FRONTIERS IN PHYSIOLOGY, vol. 5, 9 March 2015 (2015-03-09), CH, pages 4436, XP055276187, ISSN: 1664-042X, DOI: 10.1038/ncomms5436 * |
CHEN C; LIU Y; LIU R; IKENOUE T; GUAN KL; LIU Y; ZHENG P.: "TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species", J EXP MED., vol. 205, 2008, pages 2397 - 2408 |
CHIONG MARIO ET AL: "Influence of glucose metabolism on vascular smooth muscle cell proliferation", VASA, BERN, CH, vol. 42, no. 1, 1 January 2013 (2013-01-01), pages 8 - 16, XP009190260, ISSN: 0301-1526 * |
COLLER BS: "Leukocytosis and ischemic vascular disease morbidity and mortality", ARTERIOSCLER THROMB VASC BIOL., vol. 25, 2005, pages 658 - 670 |
DAWSON AG: "Oxidation of cytosolic NADH formed during aerobic metabolism in mammalian cells", TRENDS BIOCHEM SCI., vol. 4, 1979, pages 171 - 176, XP023571749, DOI: doi:10.1016/0968-0004(79)90417-1 |
DEBERARDINIS RJ; LUM JJ; HATZIVASSILIOU G; THOMPSON CG: "The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation", CELL METAB., vol. 7, 2008, pages 11 - 20 |
DRECHSLER M; MEGENS RTA; VAN ZANDVOORT M; WEBER C; SOEHNLEIN O: "Hyperlipidemai-triggered neutrophilia promotes early atherosclerosis/clinical perspectives", CIRCULATION, vol. 122, 2010, pages 1837 - 1845 |
DUTTA P; SAGER HB; STENGEL KR; NAXEROVA K; COURTIES G; SAEZ B; SILBERSTEIN L; HEIDT T; SEBAS M; SUN Y: "Myocardial infarction activates CCR2+ hematopoietic stem and progenitor cells", CELL STEM CELL, vol. 16, 2015, pages 477 - 487 |
EBERT BL; FIRTH JD; RATCLIFFE PJ: "Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct Cis-acting sequences", J BIOL CHEM., vol. 49, 1995, pages 29083 - 29089 |
ENAMI H ET AL.: "Splenic metabolic activity predicts risk of future cardiovascular events: demonstration of a cardiosplenic axis in humans", JACC CARDIOVASC IMAGING., vol. 8, 2015, pages 121 - 30, XP029197578, DOI: doi:10.1016/j.jcmg.2014.10.009 |
FLIER JS; MUECKLER MM; USHER P; LODISH HF: "Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes", SCIENCE, vol. 235, 1987, pages 1492 - 1495 |
GAN B; HU J; JIANG S; LIU Y; SAHIN E; ZHUANG L; FLETCHER-SANANIKONE E; COLLA S; WANG YA; CHIN L: "LKB1 regulates quiescence and metabolic homeostasis of hematopoietic stem cells", NATURE, vol. 468, 2010, pages 701 - 704 |
GAO M; ZHAO D; SCHOUTEDEN S; SORCI-THOMAS MG; VAN VELDHOVEN PP; EGGERMONT K; LIU G; VERFAILLIE CM; FENG Y: "Regulation of high-density lipoprotein on hematopoietic stem/progenitor cells in atherosclerosis requires scavenger receptor type BI expression", ARTERIOSCLER THROMB VASC BIOL., vol. 34, 2014, pages 1900 - 9 |
GARCIA-GARCIA HM; JANG IK; SERRUYS PW; KOVACIC JC; NARULA J; FAYAD, Z.: "Imaging plaques to predict and better manage patients with acute coronary events", CIRC. RES., vol. 114, 2014, pages 1904 - 1917 |
GAUTIER EL; WESTERTERP M; BHAGWAT N; CREMERS S; SHIH A; ABDEL-WAHAB O; LUTJOHANN D; RANDOLPH GJ; LEVINE RL; TALL AR: "HDL and Glutl inhibition reverse a hypermetabolic state in mouse models of myeloproliferative disorders", J EXP MED., vol. 210, 2013, pages 339 - 353 |
GURUMURTHY S; XIE SZ; ALAGESAN B; KIM J; YUSUF RZ; SAEZ B; TZATSOS A; OZSOLAK F; MILOS, P; FERRARI F: "The Lkbl metabolic sensor maintains haematopoietic stem cell survival", NATURE, vol. 486, 2010, pages 659 - 663, XP055280045, DOI: doi:10.1038/nature09572 |
HAG AM; PEDERSEN SF; CHRISTOFFERSEN C; BINDERUP T; JENSEN MM; JORGENSEN JT; SKOVGAARD D; RIPA RS; KJAER A.: "18)F-FDG PET imaging of murine atherosclerosis: association with gene expresion of key molecular markers", PLOS ONE, vol. 7, 2012, pages E50908 |
JANG YY; SHARKIS SJ: "A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche", BLOOD, vol. 110, 2007, pages 3056 - 3063 |
KAUPPINEN RA; SIHRA TS; NICHOLLS DG: "Aminooxyacetic acid inhibits the malate-aspartate shuttle in isolated nerve terminals and prevents the mitochondria from utilizing glycolytic substrates", BIOCHIM BIOPHYS ACTA, vol. 930, 1987, pages 173 - 8, XP025210880, DOI: doi:10.1016/0167-4889(87)90029-2 |
KIM EJ; KIM S; KANG DO; SEO HS: "Metabolic activity of the spleen and bone marrow in patients with acute myocardial infarction evaluated by 18f-fluorodeoxyglucose positron emission tomographic imaging", CIRC CARDIOVASC IMAGING., vol. 7, 2014, pages 454 - 60 |
LEE SJ; THIEN QUACH CH; JUNG KH; PAIK JY; LEE JH; PARK JW; LEE KH: "Oxidized low-density lipoprotein stimulates macrophage 18F-FDG uptake via hypoxia-inducible factor-la activation through Nox2-dependent reactive oxygen species generation", J NUCL MED., vol. 55, 2014, pages 1699 - 705, XP055276190, DOI: doi:10.2967/jnumed.114.139428 |
LIU J; CAO L; CHEN J; SONG S; LEE IH; QUIJANO C; LIU H; KEYVANFAR K; CHEN H; CAO LY: "Bmil regulates mitochondrial function and DNA damage response pathway", NATURE, vol. 459, 2009, pages 387 - 393 |
LUM JJ; BAUER DE; KONG M; HARRIS MH; LI C; LINDSTEN T; THOMPSON CB: "Growth factor regulation of autophagy and cell survival in the absence of apoptosis", CELL, vol. 120, 2005, pages 237 - 48 |
LUNT SY; VANDER HEIDEN MG: "Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation", ANNU. REV. CELL DEV. BIOL., vol. 27, 2011, pages 441 - 64 |
MACINTYRE AN; GERRIETS VA; NICHOLS AG; MICHALEK RD; RUDOLPH MC; DEOLIVEIRA D; ANDERSON SM; ABEL ED; CHEN BJ; HALE LP: "The glucose transporter Glutl is selectively essential for CD4 T cell activation and effectyor function", CELL METAB, vol. 20, 2014, pages 1 - 12 |
MIHARADA K; KARLSSON G; REHN M; RORBY E; SIVA K; CAMMENGA J; KARLSSON S: "Cripto regulates hematopoietic stem cells as hypoxic-niche-related factor through cell surface receptor GRP78", CELL STEM CELL, vol. 9, 2011, pages 330 - 344, XP028310027, DOI: doi:10.1016/j.stem.2011.07.016 |
MIYAMOTO K; ARAKI KY; NAKA K, ARAI F; TAKUBO K; YAMAZAKI S; MATSUOKA S; MIYAMOTO T; ITO K; OHMURA M; CHEN C: "Foxo3a is essential for maintenance of the hematopoietic stem cell pool", CELL STEM CELL, vol. 1, 2007, pages 101 - 112 |
MORTENSEN M; SOILLEUX EJ; DJORDJEVIC G; TRIPP R; LUTTEROPP M; SADIGHI-AKHA E; STRANKS AJ; GLANVILLE J; KNIGHT S; JACOBSEN SE: "The autophagy protein Atg7 is essential for hematopoietic stem cell maintenance", J EXP MED., vol. 208, 2011, pages 455 - 67 |
MURAKAMI T; NISHIYAMA T; SHIROTANI T; SHINOHARA Y; KAN M; ISHII K; KANAI F; NAKAZURU S; EBINA Y: "Identification of two enhancer elements in the gene encoding the type 1 glucose transporter from the mouse which are responsive to serum, growth factor, and oncogenes", J BIOL CHEM., vol. 267, 1992, pages 9300 - 6 |
MURPHY AJ; AKHTARI M; TOLANI S; PAGLER T; BIJL N; KUO CL; WANG M; SANSON M; ABRAMOWICZ S; WELCH C: "ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice", J CLIN INVEST., vol. 121, 2011, pages 4138 - 4149 |
NAKADA D; SAUNDERS TL; MORRISON S: "Lkbl regulates cell cycle and energy metabolism in haematopoietic stem cells", NATURE, vol. 468, 2010, pages 653 - 658 |
NISHIZAWA T; KANTER JE; KRAMER F; BARNHART S; SHEN X; VIVEKANANDAN-GIRI A; WALL VZ; KOWITZ J; DEVARAJ S; O'BRIEN KD: "An in vivo test of the hypothesis that glucose in myeloid cells stimulates inflammation and atherosclerosis", CELL REPORT, vol. 7, 2014, pages 356 - 65 |
NORDDAHL GL; PRONK CJ; WAHLESTEDT M; STEN G; NYGREN JM; UGALE A; SIGVARDSSON M; BRYDER D: "Accumulating mitochondrial DNA mutations drive premature hematopoietic aging phenotypes distinct from physiological stem cell aging", CELL STEM CELL, vol. 8, 2011, pages 499 - 510, XP028349998, DOI: doi:10.1016/j.stem.2011.03.009 |
OBUROGLU L; TARDITO S; FRITZ V; DE BARROS SC; MERIDA P; CRAVEIRO M; MAMEDE J; CRETENET G; MONGELLAZ C; AN X: "Glucose and glutamine metabolism regulate human hematopoietic stem cell lineage specification", CELL STEM CELL, vol. 15, 2014, pages 169 - 184 |
OLIVARES R; DUCIMETIERE P; CLAUDE JR: "Monocyte count: a risk factor for coronary heart disease?", AM J EPIDEMIOL., vol. 137, 1993, pages 49 - 53 |
PARATHATH S; YANG Y; MICK S; FISHER EA: "Hypoxia in murine atherosclerotic plaques and its adverse effects on macrophages", TRENDS CARDIOVASC MED, vol. 23, 2013, pages 80 - 4, XP028990740, DOI: doi:10.1016/j.tcm.2012.09.004 |
PIETRAS EM; REYNAUD D; KANG YA; CARLIN D; CALERO-NIETO FJ; LEAVITT AD; STUART JM; GOTTGENS B; PASSEGUE E: "Functionally distinct subsets of lineage-biased multipotent progenitors control blood production in normal and regenerative conditions", CELL STEM CELL, vol. 17, 2015, pages 35 - 46 |
ROBBINS CS; CHUDNOVSKIY A; RAUCH PJ; FIGUEIREDO JL; IWAMOTO Y; GORBATOV R; ETZRODT M; WEBER GF; UENO T; VAN ROOIJEN N: "Extramedullary hematopoiesis generates Ly-6C(high) monocytes that infiltrates atherosclerotic lesions", CIRCULATION, vol. 125, 2012, pages 364 - 74 |
ROGERS IS; TAWAKOL A: "Imaging of coronary inflammation with FDG-PET: feasibility and clinical hurdles", CURR CARDIOL REP., vol. 13, 2011, pages 138 - 144 |
ROZMAN S; YOUSEFI S; OBERSON K; KAUFMANN T; BENARAFA C; SIMON HU: "The generation of neutrophils in the bone marrow is controlled by autophagy", CELL DEATH DIFFER., vol. 22, 2015, pages 445 - 56 |
S. J. LEE ET AL: "Oxidized Low-Density Lipoprotein Stimulates Macrophage 18F-FDG Uptake via Hypoxia-Inducible Factor-1 Activation Through Nox2-Dependent Reactive Oxygen Species Generation", THE JOURNAL OF NUCLEAR MEDICINE, vol. 55, no. 10, 1 October 2014 (2014-10-01), US, pages 1699 - 1705, XP055276190, ISSN: 0161-5505, DOI: 10.2967/jnumed.114.139428 * |
SEIJKENS T; HOEKSEMA MA; BECKERS L; SMEETS E; MEILER S; LEVELS J; TJWA M; DE WINTHER MPJ; LUTGENS E: "Hypercholesterolemia-induced priming of hematopoietic stem and progenitor cells aggravate atherosclerosis", THE FASEB J., vol. 28, 2014, pages 2202 - 2213 |
SELAK MA; ARMOUR SM; MACKENZIE ED; BOULAHBEL H; WATSON DG; MANSFIELD KD; PAN Y; SIMON MC; THOMPSON CB; GOTTLIEB E: "Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase", CANCER CELL, vol. 7, 2005, pages 77 - 85 |
SIMSEK T; KOCABAS F; ZHENG J; DEBERARDINIS RJ; MAHMOUD AI; OLSON EN; SCHNEIDER, JW; ZHANG CC; SADEK HA: "The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche", CELL STEM CELL, vol. 7, 2010, pages 380 - 390 |
SWIRSKI FK; LIBBY P; AIKAWA E; ALCAIDE P; LUSCINSKAS FW; WEISSLEDER R; PITTET MJ: "Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata", J CLIN INVEST, vol. 117, 2007, pages 195 - 205, XP002526385, DOI: doi:10.1172/JCI29950 |
SWIRSKI FK; NAHRENDORF M: "Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure", SCIENCE, 2013, pages 161 - 166 |
TACKE F; ALVAREZ D; KAPLAN TJ; JAKUBZICK C; SPANBROEK R; LLODRA J; GARIN A; LIU J; MACK M; VAN ROOIJEN N: "Monocyte subsets differentially employ CCR2, CCR5, and CX3CRl to accumulate within atherosclerotic plaques", J CLIN INVEST., vol. 117, 2007, pages 185 - 194, XP002526386, DOI: doi:10.1172/JCI28549 |
TAKUBO K; GODA N; YAMADA W; IRIUCHISHIMA H; IKEDA E; KUBOTA Y; SHIMA H; JOHNSON RS; HIRAO A; SUEMATSU M: "Regulation of the HIF-1Q level is essential for hematopoietic stem cells", CELL STEM CELL, vol. 7, 2010, pages 391 - 402 |
TAKUBO K; NAGAMATSU G; KOBAYASHI CI; NAKAMURA-ISHIZU A; KOBAYASHI H; IKEDA, E; GODA N; RAHIMI Y; JOHNSON RS; SOGA T: "Regulation of glycolysis by Pdk functions as a metabolic checkpoint for cell cycle quiescence in hematopoietic stem cells", CELL STEM CELL, vol. 12, 2013, pages 49 - 61 |
TALL AR; YVAN-CHARVET L: "Cholesterol in inflammation and immune function", NAT IMMUNOL REV., vol. 15, 2015, pages 104 - 16 |
TOMOHIRO NISHIZAWA ET AL: "Testing the Role of Myeloid Cell Glucose Flux in Inflammation and Atherosclerosis", CELL REPORTS, vol. 7, no. 2, 1 April 2014 (2014-04-01), US, pages 356 - 365, XP055276493, ISSN: 2211-1247, DOI: 10.1016/j.celrep.2014.03.028 * |
TOTHOVA Z; KOLLIPARA R; HUNTLY BJ; LEE BH; CASTRILLON DH; CULLEN DE; MCDOWELL EP; LAZO-KALLANIAN S; WILLIAMS IR; SEARS C: "FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress", CELL, vol. 128, 2007, pages 325 - 339, XP055203673, DOI: doi:10.1016/j.cell.2007.01.003 |
VANDER HEIDEN MG; CANTLEY LC; THOMPSON CB: "Understanding the Warburg effect: the metabolic requirements of cell proliferation", SCIENCE, vol. 324, 2009, pages 1029 - 1033 |
WANG M; SUBRAMANIAN M; ABRAMOWICZ S; MURPHY AJ; GONEN A; WITZTUM J; WELCH C; TABAS I; WESTERTERP M; TALL AR: "Interleukin-3/Granulocyte macrophage colony-stimulating factor receptor promotes stem cell expansion, monocytosis, and atheroma macrophage burden in mice with hematopoietic ApoE deficiency", ARTERIOSCLER THROMB VASC BIOL., vol. 34, 2014, pages 976 - 984 |
WEBER GF; CHOUSTERMAN BG; HE S; FENN AM; NAIRZ M; ANZAI A; BRENNER T; UHLE F; IWAMOTO Y; ROBBINS CS: "Interleukin-3 amplifies acute inflammation and is a potential therapeutic target in sepsis", SCIENCE, vol. 347, 2015, pages 1260 - 5, XP055229899, DOI: doi:10.1126/science.aaa4268 |
WEISSMAN IL; SHIZURU JA: "The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases", BLOOD, vol. 112, 2008, pages 3543 - 53 |
YU WM; LIU X; SHEN J; JOVANOVIC 0; POHL EE; GERSON SL; FINKEL T; BROXMEYER HE; QU CK: "Metabolic regulation by the mitochondrial phosphatase PTPMT1 is required for hematopoietic stem cell differentiation", CELL STEM CELL, vol. 12, 2013, pages 62 - 74 |
YVAN-CHARVET L; PAGLER TA; GAUTIER EL; AVAGYAN S; SIRY RL; HAN S; WELCH CL; WANG N; RANDOLPH GJ; SNOECK HW: "ATP binding cassette transporters and HDL suppress hematopoietic stem cell proliferation", SCIENCE, vol. 328, 2010, pages 1689 - 1693 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114751854A (zh) * | 2022-03-23 | 2022-07-15 | 中国科学院自动化研究所 | 近红外荧光探针及其制备方法和应用 |
CN114751854B (zh) * | 2022-03-23 | 2023-09-15 | 中国科学院自动化研究所 | 近红外荧光探针及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cao et al. | Cytosolic DNA sensing promotes macrophage transformation and governs myocardial ischemic injury | |
Thapa et al. | Metabolic influence on macrophage polarization and pathogenesis | |
Sarrazy et al. | Disruption of Glut1 in hematopoietic stem cells prevents myelopoiesis and enhanced glucose flux in atheromatous plaques of ApoE−/− mice | |
Sager et al. | RNAi targeting multiple cell adhesion molecules reduces immune cell recruitment and vascular inflammation after myocardial infarction | |
Ii et al. | Endothelial progenitor cells are rapidly recruited to myocardium and mediate protective effect of ischemic preconditioning via “imported” nitric oxide synthase activity | |
Vergadi et al. | Early macrophage recruitment and alternative activation are critical for the later development of hypoxia-induced pulmonary hypertension | |
Yap et al. | Macrophages in cardiac remodelling after myocardial infarction | |
Chavakis et al. | Homing of progenitor cells to ischemic tissues | |
US20220257755A1 (en) | Combination therapy for the treatment of autoimmune diseases | |
Chi et al. | Exerkine fibronectin type-III domain-containing protein 5/irisin-enriched extracellular vesicles delay vascular ageing by increasing SIRT6 stability | |
Hardaway et al. | IL-1β, RAGE and FABP4: targeting the dynamic trio in metabolic inflammation and related pathologies | |
BR112012017150B1 (pt) | Formulação farmacêutica, recipiente farmacêutico, e kit | |
Ohshima et al. | Intraperitoneal and intravenous deliveries are not comparable in terms of drug efficacy and cell distribution in neonatal mice with hypoxia–ischemia | |
Paquet et al. | Effect of N-acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof-of-concept study | |
Chen et al. | Soluble epoxide hydrolase inhibition provides multi-target therapeutic effects in rats after spinal cord injury | |
Iqbal et al. | Inducible nitric oxide synthase (NOS-2) in subarachnoid hemorrhage: Regulatory mechanisms and therapeutic implications | |
AU2015270925A1 (en) | Methods and compositions for immunomodulation | |
Ehrentraut et al. | Antagonism of lipopolysaccharide-induced blood pressure attenuation and vascular contractility | |
Tan et al. | Dynamic aging: channeled through microenvironment | |
Zhang et al. | S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity | |
Hałucha et al. | Protective role of platelets in myocardial infarction and ischemia/reperfusion injury | |
Ciryam et al. | Interleukin-6 in Traumatic Brain Injury: A Janus-Faced Player in Damage and Repair | |
Luo et al. | Perfluorotributylamine-loaded albumin nanoparticles downregulate platelet-derived TGFβ to inhibit tumor metastasis | |
WO2017129558A1 (fr) | Méthodes permettant de prévoir ou de traiter la septicémie et les maladies cardiométaboliques induites par la myélopoïèse | |
EP2802342B1 (fr) | Peptide et ses utilisations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17701146 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17701146 Country of ref document: EP Kind code of ref document: A1 |